These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11569610)

  • 1. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
    Inoue A; Nakata Y
    Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole].
    Costentin J
    Encephale; 2009 Feb; 35(1):66-72. PubMed ID: 19250996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D2 receptor partial agonists in the treatment of schizophrenia -example of brexpiprazole.
    Bliźniewska-Kowalska KM; Gałecki P
    Psychiatr Pol; 2024 Aug; 58(4):581-593. PubMed ID: 39378141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review.
    Mallet J; Gorwood P; Le Strat Y; Dubertret C
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):651-664. PubMed ID: 31406978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 2-bromoterguride, a dopamine D
    Tarland E; Franke RT; Fink H; Pertz HH; Brosda J
    Psychopharmacology (Berl); 2018 Jan; 235(1):99-108. PubMed ID: 28971230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
    Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
    J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
    Simon N; Azorin JM
    Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The place of partial agonism in psychiatry: recent developments.
    Ohlsen RI; Pilowsky LS
    J Psychopharmacol; 2005 Jul; 19(4):408-13. PubMed ID: 15982997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
    Reynolds GP
    J Psychopharmacol; 2021 Sep; 35(9):1030-1036. PubMed ID: 34256637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.